On May 27, 2020 Synlogic (Nasdaq: SYBX) reported that will host its first Virtual R&D Event which will include presentations from members of the Synlogic executive team providing an in-depth review of Synlogic’s Synthetic Biotic platform and programs for the treatment of metabolic diseases, inflammatory and immune disorders, and cancer (Press release, Synlogic, MAY 27, 2020, View Source [SID1234558538]). In addition, guest speaker David S. Goldfarb, M.D., Professor of Medicine and Physiology, NYU School of Medicine, Clinical Chief, Nephrology Division, NYU Langone Health, Chief, Nephrology Section, New York VA Medical Center, will present an overview of enteric hyperoxaluria and a patient perspective.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Registration information for the event can be accessed under "Event Calendar" in the Investors & Media section of the Synlogic website. The R&D Event presentations are scheduled to begin at 12:30 pm ET today, May 27, 2020. A live audio webcast of the presentation and a slide deck will be available via the company’s Investor Relations website. Following the live webcast, an archived version will be available on the website for 90 days.